Malaria - Pipeline Review, Q1 2011

Global Markets Direct, March 2011, Pages: 166

Malaria - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Malaria - Pipeline Review, Q1 2011', provides an overview of the Malaria therapeutic pipeline. This report provides information on the therapeutic development for Malaria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. 'Malaria - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Malaria.
- A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Malaria pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Malaria.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Malaria therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Malaria Overview
Therapeutics Development
An Overview of Pipeline Products for Malaria
Malaria Therapeutics under Development by Companies
Malaria Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Malaria Therapeutics - Products under Development by Companies
Malaria Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Malaria Therapeutics Development
Sanofi-Aventis
GlaxoSmithKline plc
Antigenics, Inc.
Eastland Medical Systems Limited
Pfizer Inc.
Sigma-Tau S.p.A.
Optimer Pharmaceuticals, Inc.
Crucell N.V.
Mymetics Corporation
Patrys Limited
Advanced Life Sciences Holdings, Inc.
Alnylam Pharmaceuticals, Inc
Cytos Biotechnology AG
Sinobiomed, Inc.
PolyMedix, Inc.
Affitech A/S
Aeras Global Tb Vaccine Foundation
Bharat Biotech International Limited
Jenrin Discovery, Inc.
Treague Ltd
Dilafor AB
Okairos
Spirogen Ltd.
Medicines for Malaria Venture (MMV)
Sanaria Inc.
iBio, Inc.
PepTcell Limited
Genocea Biosciences, Inc.
PALUMED S.A.
VLP Biotech, Inc.
Jomaa Pharma GmbH
Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.
Malaria - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
ArTiMist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nuartez - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zithromax + Chloroquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mosquirix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QS-21 Stimulon Adjuvant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Pyramax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eurartesim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RBx11160 - Drug Profile
Product Description
Mechanism of Action
Sulphadoxine + Pyrimethamine + Mefloquine + Chlorproguanil + Dapsone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artesunate + Mefloquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + Sulphadoxin + Pyrimethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + Artesunate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Coartem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + Artesunate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artemether + Lumefantrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + (Sulfadoxine + Pyrimethamine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + Artesunate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artekin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + Artesunate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artemether + Lumefantrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
20% Diethyltoluamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artemether + Lumefantrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artesunate for Vivax Malaria - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chloroquine for Vivax Malaria - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chloroquine + Primaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ITN + RDT + Amodiaquine + Artimisinin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Primaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artesunate + Amodiaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulphadoxine + Pyrimethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + Sulfadoxine + Pyrimethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artekin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Azithromycin + Artesunate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfadoxine + Pyrimethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Azithromycin + Sulphadoxine + Pyrimethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artesunate + Mefloquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artekin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trimethoprim + Sulfamethoxazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfadoxine + Pyrimethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dihydroartemisinin + Piperaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lopinavir + Ritonavir + Zidovudine + Lamivudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + artesunate (AQ/AS) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chloroquine + Malarone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chloroquine + Azithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dihydroartemisinin + Piperaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfadoxine + Pyrimethamine + Artesunate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfadoxine + Pyrimethamine + Piperaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sulfadoxine + pyrimethamine + piperaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfadoxine-Pyrimethamine + Artesunate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sulfalene-pyrimethamine + amodiaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulphadoxine + Pyrimethamine + Primaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulphadoxine-pyrimethamine + Primaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mefloquine + Artesunate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Azithromycin + Sulphadoxine + Pyrimethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + selenium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + vitamin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + Vitamin E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amodiaquine + Zinc - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artesunate + selenium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artesunate + vitamin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artesunate + vitamin E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artesunate + Zinc - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mefloquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfadoxine + Pyrimethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosmidomycin + clindamycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chloroquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chloroquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorproguanil + Dapsone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cotrimoxazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cotrimoxazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dihydroartemisinin + Piperaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfadoxine + Pyrimethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Duocortexin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chloroquine + Artesunate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dihydroartemisinin-piperaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Malaria Therapeutics - Discontinued Products
Malaria - Featured News
Nov 03, 2010: Cempra's Solithromycin Demonstrates Potent In Vitro And In Vivo Activity Against Malaria
Nov 02, 2010: Advanced Life Sciences Announces US Army Collaboration To Research And Develop Restanza For Treatment Of Malaria
Jul 12, 2010: Cumberland 's Caldolor Injection Shown To Significantly Reduce Fever In Malaria Patients In Newly Published Clinical Trial
Jul 09, 2010: US FDA Warns Of Risks With Unapproved Use Of Qualaquin
Jun 16, 2010: Mymetics Completes Phase Ib Malaria Vaccine Clinical Trial In Children In Tanzania
May 26, 2010: Advanced Life Sciences' Restanza Shows Efficacy Against Malaria
Apr 15, 2010: Genocea Biosciences Enters Into Cooperative Research and Development Agreement with U.S. Military to Develop Malaria Vaccine
Mar 30, 2010: Ikaria Acquires New Drug Application For Lucassin
Mar 12, 2010: PolyMedix Presents PMX-30063 Antibiotic Phase IB Clinical Data At 8th World Congress On Trauma, Shock, Inflammation And Sepsis
Feb 22, 2010: Sanaria Wins Multi-Year NIH Phase II SBIR Grant To Develop Genetically Attenuated Whole Parasite Malaria Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Malaria, Q1 2011
Products under Development for Malaria – Comparative Analysis, Q1 2011
Comparative Analysis by Late Stage Development, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q1 2011
Sanofi-Aventis, 2011
GlaxoSmithKline plc, 2011
Antigenics, Inc., 2011
Eastland Medical Systems Limited, 2011
Pfizer Inc., 2011
Sigma-Tau S.p.A., 2011
Optimer Pharmaceuticals, Inc., 2011
Crucell N.V., 2011
Mymetics Corporation, 2011
Patrys Limited, 2011
Advanced Life Sciences Holdings, Inc., 2011
Alnylam Pharmaceuticals, Inc, 2011
Cytos Biotechnology AG, 2011
Sinobiomed, Inc., 2011
PolyMedix, Inc., 2011
Affitech A/S, 2011
Aeras Global Tb Vaccine Foundation, 2011
Bharat Biotech International Limited, 2011
Jenrin Discovery, Inc., 2011
Treague Ltd, 2011
Dilafor AB, 2011
Okairos, 2011
Spirogen Ltd., 2011
Medicines for Malaria Venture (MMV), 2011
Sanaria Inc., 2011
iBio, Inc., 2011
PepTcell Limited, 2011
Genocea Biosciences, Inc., 2011
PALUMED S.A., 2011
VLP Biotech, Inc., 2011
Jomaa Pharma GmbH, 2011
Shanghai Wanxing Bio-Pharmaceutical Co. Ltd., 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products

List of Figures
Number of Products under Development for Malaria, Q1 2011
Products under Development for Malaria – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Late Stage Products, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Discovery and Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011

Customers who bought this item also bought

• Malaria - Pipeline Review, Q4 2010
• London School of Hygiene & Tropical Medicine - Developmental Therapeutics Review - Q1 2011
• Global Malaria Pipeline Capsule - 2013
• Nausea - Pipeline Review, H2 2012
• Global Malaria Drug Pipeline Capsule - 2011
• Global Malaria Drug Pipeline Capsule - 2012 Update
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Other Hematological Disorders - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2012